secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2023-05-17T23:59:59+00:00
Accession:  0001628280-23-018655
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx FDA accepts XPHOZAH resubmission; PDUFA Oct 17, 2023
------------------------------------------------------------

- FDA accepted resubmission of NDA for XPHOZAH (tenapanor) for serum phosphate control in dialysis patients.
- FDA designated class 2 review with six-month review period; user fee goal date October 17, 2023.
- Ardelyx expects XPHOZAH to be commercially available in Q4 2023 following potential FDA approval.
- NDA supported by over 1,200 patients in Phase 3 trials (PHREEDOM, BLOCK, AMPLIFY) that met primary endpoints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023018655/0001628280-23-018655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023018655/ardx-20230517.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-018655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer